TR
Traws Pharma, Inc.
TRAW · NASDAQ
$0.59 +11.34% (+$0.06)
1M -5.95%
Market Cap $8.09M
P/E Ratio 0.88x
Div. Yield -
ROE -
Bulios Fair Price
$0.83
41.6% upside
Current Price
$0.59
Undervalued Fair Value Overvalued
According to Bulios Fair Price, TRAW is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
87 /100
Cheap P/E 0.88x
P/S 2.90x
EV/EBITDA N/A
Growth
100 /100
Growing Rev. growth 131.12%
EPS growth N/A
FCF growth N/A
Profitability
40 /100
Moderate Gross margin 100.00%
Net margin 328.67%
Op. margin 640.68%
Quality
83 /100
Excellent ROIC 3,379.02%
ROA 86.37%
Asset turnover 0.26x
Debt
20 /100
High Current ratio 0.72x
Debt/Equity N/A
Int. coverage N/A
Stability
9 /100
Unstable Beta 1.61x
Rev. volatility 655.01%
EPS volatility 80.25%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about TRAW
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Iain D. Dukes
Employees
7
Headquarters
Newtown
Upcoming events
12 NOV
Earnings
Upcoming earnings report